But which ones could be buys in April?

Let's look at three that analysts are currently recommending as buys to their clients. They are as follows:

Centuria Industrial REIT (ASX: CIP)

UBS thinks that Centuria Industrial REIT could be a top ASX dividend share to buy in April.

It is an industrial property company that owns a portfolio of high-quality industrial assets that is situated in urban infill locations throughout Australia and is underpinned by a quality and diverse tenant base.

UBS believes the company is positioned to pay dividends per share of 17 cents in FY 2026 and in FY 2027. Based on its current share price of $2.96, this would mean dividend yields of 5.75%.

The broker also sees 15% upside with its buy rating and $3.40 price target.

Sonic Healthcare Ltd (ASX: SHL)

Another ASX dividend share that could be a top buy in April is Sonic Healthcare.

It is a leading pathology and diagnostic imaging provider with operations across Australia, Europe, and the United States.

The team at Bell Potter is positive and thinks it could be a great option. This is based on its belief that the company's performance is about to improve meaningfully. The broker highlights that this is expected to be "driven by right sizing the business, the impact of acquisitions in FY24 and normalising organic operations post COVID."

With respect to dividends, Bell Potter is forecasting Sonic Healthcare to pay dividends per share of $1.09 in FY 2026 and then $1.11 in FY 2027. Based on its current share price of $20.53, this represents dividend yields of 5.3% and 5.4%, respectively.

Bell Potter has a buy rating and $28.75 price target on its shares, which implies potential upside of 40%.

Universal Store Holdings Ltd (ASX: UNI)

A third ASX dividend share that could be a top pick for income investors in April is Universal Store.

It is the youth fashion retailer behind the eponymous Universal Store brand, as well as Thrills and Perfect Stranger.

Morgans believes the company's positive form can continue and expects this to underpin further dividend increases.

It is forecasting fully franked dividends of 41 cents per share in FY 2026 and 46 cents per share in FY 2027. Based on its current share price of $7.32, this equates to dividend yields of 5.6% and 6.3%, respectively.

Morgans has a buy rating and $10.60 price target on its shares. This implies potential upside of 45% for investors.

The post 3 cheap ASX dividend shares offering 5% to 6% yields (and major upside) appeared first on The Motley Fool Australia.

ASX 200 shares soared 2.6% to an intraday peak of 8,804 points in morning trading on Tuesday.

Leading the market today are Guzman Y Gomez Ltd (ASX: GYG) shares, up 18%, and Nextdc Ltd (ASX: NXT), up 12%.

However, some ASX shares are bucking the trend.

Here are six stocks that hit 52-week lows today.

Sonic Healthcare Ltd (ASX: SHL)

Sonic Healthcare is one of several ASX healthcare shares trading at multi-year lows these days.

The sector faces multiple headwinds, including currency changes, US tariffs, and higher labour costs and other expenses.

The Sonic Healthcare share price fell to a decade-low of $18.88 today.

This ASX healthcare share has fallen 13% in the year to date (YTD) and 21% over the past year.

Ord Minnett has a hold rating on Sonic Healthcare with a 12-month share price target of $24.

Stockland Corp Ltd (ASX: SGP)

The Stockland share price fell to a 52-week low of $4.01 today.

Stockland shares are down 30% YTD.

In a separate article, my colleague Aaron has delved into the reasons this ASX property share has tanked in 2026.

Macquarie has just reiterated its buy rating on Stockland shares with a target price of $4.42.

Endeavour Group Ltd (ASX: EDV)

The Endeavour share price fell to a record low of $3.13 on Tuesday.

Endeavour shares have tumbled 14% YTD.

Citi recently downgraded this ASX consumer staples share to a hold rating.

The broker reduced its 12-month target from $4.30 to $3.70.

Atlas Arteria Group Ltd (ASX: ALX)

The Atlas Arteria share price fell to a nine-year low of $4.21 today.

Shares in the toll roads operator have fallen 13% YTD.

Last week, Morgan Stanley maintained its hold rating on Atlas Arteria shares.

The broker reduced its share price target from $5.06 to $4.96.

Lendlease Group (ASX: LLC)

The Lendlease share price dropped to an all-time low of $3.10 on Tuesday.

The ASX real estate share has fallen 39% in 2026.

Today, Macquarie reiterated its buy rating with a 12-month price target of $4.99.

Healius Ltd (ASX: HLS)

The Healius share price dropped to a record low of 51 cents today.

The ASX healthcare share has declined 43% YTD.

Goldman Sachs reiterated its sell rating on Healius shares last month.

The broker lowered its price target from 66 cents to 57 cents.

The post 6 ASX shares hitting 52-week lows amid today's market rally appeared first on The Motley Fool Australia.

Healthcare shares are facing many headwinds, as portfolio managers Joe Koh and Elan Miller from Blackwattle explain:

The sector as a whole has faced multiple headwinds, including currency and tariffs for the large multinationals and labour and cost pressures for the domestic players.

Today, eight of the 10 largest ASX 200 healthcare shares are trading at or close to multi-year or 52-week lows.

Does this present a buying opportunity?

Let's see what the experts say about three of these ASX 200 healthcare shares.

Sonic Healthcare Ltd (ASX: SHL)

The Sonic Healthcare share price fell to a decade-low of $19.57 last week.

This ASX 200 healthcare share has fallen 9.7% in the year to date (YTD) and 21.3% over the past year.

Last week, Ord Minnett issued a new note on Sonic Healthcare shares.

The broker maintained its hold rating with an unchanged target of $24.

Ord Minnett commented:

Ord Minnett finds it difficult to be constructive on Sonic given its inability to generate meaningful organic growth even after $3.3 billion of acquisitions over the past seven years.

There are undoubtedly some benefits from M&A, but other factors, such as price cuts and customer quotas specific to heathcare in its various markets, along with run-of-the mill costs such as wages and rents, appear to have constrained any meaningful earnings growth.

This view leads us to maintain our Hold recommendation despite the apparent value on offer.

Cochlear Ltd (ASX: COH)

The Cochlear share price tumbled to a six-year low of $160 last week.

This ASX 200 healthcare share has fallen 36.1% YTD and 36.4% over the past year.

Wilsons says Cochlear shares are trading at "a compelling entry point".

The broker commented:

Cochlear trades on a forward P/E multiple of ~26x, representing a >10 year low and a material discount to its 10-year average of ~42x.

We view this as a compelling entry point for a high-quality business ahead of accelerating earnings growth.

Wilsons expects the launch of Cochlear's Nucleus Nexa product to drive sales growth over the medium term.

Cochlear is approaching an inflection point in its earnings growth trajectory, supported by the ongoing global rollout of Nucleus Nexa (approved in mid-2025), which is its most significant product launch in over two decades.

Nexa's upgradeable firmware architecture represents a step-change in implant technology, enabling ongoing improvements in sound processing, connectivity and battery life via its Smart Sync app.

The rollout over the next few years should support ~10% CI unit growth over the medium term, with potential upside toward the mid-teens, while recurring implant upgrades will extend the Nexa's product cycle, supporting a longer duration of growth.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price crumbled to a two-year low of $107.75 late last month.

This ASX 200 healthcare share has fallen 49.3% YTD and 43.5% over the past year.

Pro Medicus shares are experiencing a period of correction after a ripsnorting two-year run through to mid 2025.

The Pro Medicus share price hit a record $336 per share in July last year.

Bell Potter has a buy rating and $240 price target on Pro Medicus shares.

The broker explains:

The company continues to announce new contract wins on a regular basis as the drivers of interest in its product offering remain firmly in place. The entire radiology industry is headed to cloud based (off premises) archiving. Put simply, the Visage 7 viewer, Workflow and Archive are the fastest and most advanced tools for the retrieval and viewing of large radiology files.

The platform is immensely scalable and relatively easily installed, providing it with a sustainable competitive advantage over the likes of peers Intelerad, Sectra, Philips and GE Healthcare. The company is conservatively managed and well owned by large institutional investors while the two founders continue to have a controlling stake.

The post 3 ASX 200 healthcare shares at multi-year lows appeared first on The Motley Fool Australia.

The ASX 200 stock is a leading healthcare provider with specialist operations in laboratory medicine, pathology, radiology, general practice medicine, and corporate medical services.

The company highlights that its diagnostic and clinical services are provided by more than 2,200 pathologists, radiologists, and other clinicians, and approximately 18,000 employees in science-based roles, including radiographers, sonographers, technicians and nurses.

Clearly, it is an impressive operation. But is this ASX 200 stock a buy? Let's see what Ord Minnett is saying about Sonic Healthcare.

What is Ord Minnett saying about this ASX 200 stock?

Unfortunately, the broker thinks that the company could be negatively impacted by proposed changes to medical fees in Germany. It said:

Ord Minnett has reviewed the medium-term outlook for Sonic Healthcare (SHL) given the increasing likelihood of reforms to Germany's Gebührenordnung für Ärzte (GOA), the medical fee schedule for patients with private health insurance that covers a wide range of consultation fees and outpatient services, including, in Sonic's case, laboratory fees.

These reforms pose a risk to Sonic given GOA reimbursements account for almost 1/3 of its German division's revenue, and equate to nearly 8% of group revenue, with drafts of the reforms aiming for a cut in laboratory fee reimbursements, on average, of 29% (although we expect this will be negotiated down as the legislation is developed and we model 20% in our numbers). The timing and details of mooted changes to the GOÄ are uncertain, although our talks with the industry indicate likely implementation from January 2028.

Should you buy, hold, or sell?

In light of this uncertainty and Sonic's lack of organic growth, the broker has put a hold rating and $24.00 price target on its shares.

However, this still implies potential upside of 18% for investors, which is better than what some buy recommendations offer.

Commenting on its recommendation, Ord Minnett said:

Post our review, we have made very minor changes to our near-term EPS forecasts and our target price remains at $24.00. Ord Minnett finds it difficult to be constructive on Sonic given its inability to generate meaningful organic growth even after $3.3 billion of acquisitions over the past seven years.

There are undoubtedly some benefits from M&A, but other factors, such as price cuts and customer quotas specific to healthcare in its various markets, along with run-of-the mill costs such as wages and rents, appear to have constrained any meaningful earnings growth. This view leads us to maintain our Hold recommendation despite the apparent value on offer.

The post Buy, hold, sell: What is Ord Minnett saying about this popular ASX 200 stock? appeared first on The Motley Fool Australia.

More than 400 companies in the ASX All Ords fell yesterday, with some hitting new 52-week lows.

Brokers say these ASX All Ords shares are good buys in today's market.

Here are their 12-month share price targets on each stock.

Objective Corporation Ltd (ASX: OCL)

The Objective Corporation share price fell to a 52-week low of $11.68 on Thursday.

The ASX All Ords tech share is down 29% in the year to date (YTD), and down 22% over the past 12 months.

Following the stock's recent fall, Morgans upgraded its rating from accumulate to buy.

However, the broker reduced its 12-month price target from $20 to $16.70.

Morgans said:

We see tailwinds remaining supportive of OCL's long-term growth momentum.

Generation Development Group Ltd (ASX: GDG)

The Generation Development Group share price fell to a 52-week low of $3.71 yesterday.

The ASX All Ords financial share is down 35% YTD, and down 21% over the past 12 months.

Morgans recently retained its buy rating but reduced its 12-month price target from $7.97 to $6.66.

The broker said:

We believe GDG has a great story, and management has executed well over time.

Jumbo Interactive Ltd (ASX: JIN)

The Jumbo Interactive share price dropped to a 52-week trough of $7.66 yesterday.

This ASX All Ords gaming share has fallen 32% YTD, and is down 25% over the past 12 months.

Jarden has a buy rating on Jumbo Interactive shares with a price target of $12.70.

Cleanaway Waste Management Ltd (ASX: CWY)

The Cleanaway Waste Management share price fell to a 52-week low of $2.31 on Thursday.

The ASX All Ords industrials share has fallen 11% YTD, and dropped 9% over 12 months.

Morgans has a buy rating with a 12-month price target of $3.11.

The broker commented:

1H26 was a mixed bag, with a minor bottom-of-the-range EBIT guidance upgrade.

Next catalyst is the investor strategy day planned for 21 April.

Earnings forecast adjustments are minimal, cashflow downgrades more material.

Sonic Healthcare Ltd (ASX: SHL)

The Sonic Healthcare share price fell to a 52-week low of $20.50 on Thursday.

The ASX All Ords healthcare share has deteriorated 8% YTD and 20% over the past year.

Macquarie has an outperform rating on Sonic Healthcare with a price target of $27.50.

Saluda Medical Inc (ASX: SLD)

Fellow ASX All Ords healthcare share, Saluda Medical, dropped to a 52-week low of 80 cents yesterday.

The Saluda Medical share price has tumbled 42% YTD, and is down 35% over 12 months.

Morgans has a speculative buy rating with a 12-month price target of $3.07.

The broker said:

1H26 showed solid revenue momentum, improving margins, and continued expansion of the US sales force, supporting confidence in a stronger 2H.

Reiteration of FY26 revenue guidance (US$85m) added further comfort and now expects to exceed IPO metrics for gross margin, adjusted EBITDA and cash burn.

The post 6 ASX All Ords shares at 52-week lows: Experts say buy appeared first on The Motley Fool Australia.

When I look for ASX dividend stocks, I tend to focus on businesses that combine reliable income with solid underlying operations. A dividend is great, but it is even better when it is supported by a strong business model and the potential for earnings to grow over time.

With that in mind, here are three dividend-focused ASX stocks I would be looking at this month.

Commonwealth Bank of Australia (ASX: CBA)

I think it is impossible to talk about dividend investing on the ASX without mentioning Commonwealth Bank of Australia.

The bank has built a reputation as the highest-quality lender in Australia thanks to its dominant deposit base, strong technology platform, and disciplined approach to lending.

CBA's dividend yield may not look spectacular at first glance because the share price has rallied strongly over the past few years. However, it still provides a healthy income stream.

Consensus estimates currently point to a fully franked dividend of about $5.20 per share in FY2026. Based on the current CBA share price of $171.09, that implies a yield of a little over 3%, before taking franking credits into account.

For income investors, those franking credits make a meaningful difference. They can significantly boost the effective yield on an after-tax basis.

What I like most about CBA is the consistency. Banks will always face economic cycles, but CBA has shown time and again that it can generate strong profits and maintain dividends through changing conditions.

Sonic Healthcare Ltd (ASX: SHL)

Another ASX dividend stock that stands out to me is Sonic Healthcare.

Sonic operates one of the world's largest medical diagnostics businesses, with laboratories and pathology services across Australia, Europe, and the United States.

Healthcare demand tends to be relatively stable, which helps make Sonic's earnings more predictable than many other industries. That stability can translate into reliable dividends over time.

Consensus forecasts currently suggest Sonic could pay partially franked dividends of around $1.10 per share this financial year. With its shares trading at about $21.28, that equates to a dividend yield of just over 5%.

In my view, the combination of defensive healthcare demand and a solid dividend yield makes Sonic an appealing option for income-focused investors.

Harvey Norman Holdings Ltd (ASX: HVN)

The third ASX dividend stock on my list is Harvey Norman.

Retail businesses can sometimes produce strong dividends when they are run conservatively and generate healthy cash flow. I think Harvey Norman is a good example of that.

The company's unique franchise model allows it to earn income from both retail operations and property ownership. That property exposure has historically provided a strong asset backing for the business.

Consensus estimates predict Harvey Norman will pay around 31 cents per share in fully franked dividends this year. With the share price currently around $5.24, that represents a dividend yield of roughly 6%.

For investors seeking higher income, that yield could be particularly appealing.

Foolish takeaway

Dividend investing isn't just about chasing the highest yield. In my experience, the best income stocks are usually backed by strong businesses that can keep generating cash flow year after year.

Commonwealth Bank, Sonic Healthcare, and Harvey Norman each offer a combination of income potential and established business models. For that reason, they are three ASX stocks I think are worth considering.

The post My 3 best ASX dividend-focused stocks to buy in March appeared first on The Motley Fool Australia.

But for long-term investors, pullbacks can also create opportunities to lock in attractive dividend yields.

These ASX dividend shares offer a combination of income potential and established businesses.

Sonic Healthcare

This ASX dividend share is one of the world's largest medical diagnostics providers, operating laboratories and pathology services across Australia, Europe, and North America. The company's scale and global footprint are major strengths.  

Another positive is the long-term demand outlook. Healthcare testing and diagnostics are essential services, and aging populations across developed markets should support steady demand for Sonic's services over time.

However, there are risks investors should keep in mind. Healthcare shares are exposed to government funding changes and regulatory shifts, which can affect margins. Rising wages in the healthcare sector are also a challenge for pathology operators.

Macquarie has recently assigned the ASX dividend share an outperform rating with a $27.50 price target. This points to a 25% upside over 12 months.

For income investors, the broker expects the company to pay partially franked dividends of 104 cents per share in FY2026 and 100 cents per share in FY2027.

At the current share price of $21.97, this equates to dividend yields of approximately 4.7% for FY2026 and 4.55% for FY2027.

Super Retail Group

The ASX dividend share is the retailer behind well-known brands including Supercheap Auto, Rebel, BCF, and Macpac.

A key strength of the business is its brand diversification. By operating across multiple retail categories, Super Retail reduces reliance on any single segment of consumer spending. The group also generates strong operating cash flow, which supports dividends and store expansion.

The main risk for the ASX dividend share is its exposure to consumer spending cycles. If economic conditions weaken or household budgets tighten, sales across discretionary retail categories can fall. Retail competition and promotional activity can also weigh on margins.

Even so, this ASX dividend share is known for generous shareholder returns. The company currently pays about 96 cents per share annually in dividends, offering a yield of roughly 6.5%, with payments typically made twice a year.

Most analysts rate the dividend stock a buy. They have set the average 12-month price target at $16.66, implying a 13% upside. This could bring the year's total earnings to 19.5%.

Harvey Norman Holdings

Harvey Norman is one of Australia's most recognisable retailers, selling electronics, furniture, bedding, and appliances through a large franchise network. One of the company's biggest strengths is its property portfolio, as many stores sit on land owned by the group.

This property ownership helps underpin the balance sheet and can provide an additional source of value beyond the retail operations. Harvey Norman also generates strong cash flow from its franchise model, which supports shareholder distributions.

However, the ASX dividend share is still exposed to the consumer cycle. Sales of big-ticket household goods can slow when interest rates are high or when housing markets weaken. Competition from online retailers is another ongoing challenge.

Macquarie remains positive on the ASX dividend share. It believes the company is positioned to pay fully-franked dividends per share of 27.8 cents in FY 2026 and 31.2 cents in FY 2027. Based on its current share price of $5.46, this represents dividend yields of 5.1% and 5.7%, respectively.

The broker has a buy rating and $6.60 price target on the retail stock. This points to a 23% upside at current price levels.

The post 3 ASX dividend shares to buy today with $5,000 appeared first on The Motley Fool Australia.

They have recently been recommended as buys by brokers in March. Here's why they could be top picks for income investors with $3,000 to put to work in the share market:

Cedar Woods Properties Limited (ASX: CWP)

Bell Potter thinks Cedar Woods could be an ASX dividend stock to buy this month.

It is one of Australia's leading property companies, owning a high-quality portfolio that is diversified by geography, price point, and product type. The broker believes that this leaves it well-positioned to be a big winner from Australia's chronic housing shortage.

Bell Potter expects this to support dividends per share of 39 cents in FY 2026 and then 41 cents in FY 2027. Based on its current share price of $8.73, this equates to 4.5% and 4.7% dividend yields, respectively.

The broker has a buy rating and $10.20 price target on its shares.

Premier Investments Ltd (ASX: PMV)

Another ASX dividend stock to consider for income is Premier Investments.

It is the owner of popular retail brands Smiggle and Peter Alexander, as well as a sizeable stake in appliance manufacturer Breville Group Ltd (ASX: BRG). These assets are consistently generating strong free cash flow, which is usually returned to shareholders in the form of dividends.

Macquarie is positive on this one, especially given its belief that the Peter Alexander brand is being significantly undervalued.

As for income, it expects fully franked dividends of 79 cents per share in FY 2026 and then 90.3 cents per share in FY 2027. Based on its current share price of $12.87, this equates to dividend yields of 6.1% and 7%, respectively.

The broker currently has an outperform rating and $16.20 price target on the shares.

Sonic Healthcare Ltd (ASX: SHL)

A final ASX dividend stock to consider according to analysts is Sonic Healthcare.

It is a global medical diagnostics company, operating laboratories and collection centres across Australia, Europe, and the United States. Its services are tied to healthcare demand rather than economic cycles, which can provide a degree of earnings resilience.

Macquarie is also positive on this one and is recommending Sonic Healthcare to clients.

The broker recently put an outperform rating and $27.50 price target on its shares.

In terms of income, Macquarie is forecasting partially franked dividends of 104 cents per share in FY 2026 and 100 cents per share in FY 2027. Based on the current share price of $23.01, this implies dividend yields of 4.5% and 4.35%, respectively.

The post 3 ASX dividend stocks to buy with $3,000 in March appeared first on The Motley Fool Australia.

Will the market be able to bounce back from this on Wednesday? Here are five things to watch:

ASX 200 to fall

The Australian share market looks set to fall again on Wednesday after a poor night on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 104 points or 1.1% lower. In late trade in the United States, the Dow Jones is down 0.5%, the S&P 500 is down 0.75% and the Nasdaq is 0.9% lower. The Dow Jones was down 2% at one stage before recovering.

Oil prices jump again

ASX 200 energy shares Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a good session on Wednesday after oil prices stormed higher overnight. According to Bloomberg, the WTI crude oil price is up 5% to US$74.79 a barrel and the Brent crude oil price is up 5% to US$81.63 a barrel. This was driven by threats by Iran to close the Strait of Hormuz.

ASX 200 shares going ex-div

Another group of ASX 200 shares are going ex-dividend today and could trade lower. This includes Chemist Warehouse owner Sigma Healthcare Ltd (ASX: SIG), healthcare company Sonic Healthcare Ltd (ASX: SHL), and supermarket giant Woolworths Group Ltd (ASX: WOW). The latter will be paying a fully franked 45 cents per share dividend next month on 2 April.

Gold price tumbles

ASX 200 gold shares Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) could have a difficult session on Wednesday after the gold price sank overnight. According to CNBC, the gold futures price is down 3.6% to US$5,121 an ounce. A strong US dollar and higher rate bets put pressure on the precious metal.

Buy Life360 shares

Life360 Inc. (ASX: 360) shares are undervalued according to analysts at Bell Potter. This morning, in response to its FY 2025 results, the broker has retained its buy rating on the family safety technology company's shares with a trimmed price target of $40.00. It said: "2025 revenue of US$489m was slightly above our forecast of US$488m and VA consensus of US$486m and was top end of the US$486-489m guidance range. Adjusted EBITDA of $93m, however, was a beat versus our forecast of US$90m and VA consensus of US$88m and was also above the US$87-92m guidance range. Cash at year end was US$495m which was ahead of our forecast of US$476m."

The post 5 things to watch on the ASX 200 on Wednesday appeared first on The Motley Fool Australia.

In order to receive a dividend, you must own the ASX share before its ex-dividend date.

Here is a sample of the large number of ASX All Ords shares with ex-dividend dates next week.

ASX All Ords shares about to go ex-dividend

Which companies will we hear from today?

The big one today is the half-yearly report from supermarket network Coles Group Ltd (ASX: COL).

Woolworths shares ripped this week after the ASX All Ords consumer staples giant reported a 16% profit lift to $859 million for 1H FY26.

We'll also hear from TPG Telecom Ltd (ASX: TPG), Michael Hill International Ltd (ASX: MHJ), and Pexa Group Ltd (ASX: PXA).

The latest report from The Star Entertainment Group Ltd (ASX: SGR) will also be interesting, as investors seek further news on the turnaround plan for the beleaguered casino operator.

Yesterday, Star Entertainment shares bounced on news of a debt refinancing deal, including extra liquidity to fund the turnaround plan.

The post 35 ASX All Ords shares with ex-dividend dates next week appeared first on The Motley Fool Australia.

Here are two high-quality ASX stocks, Sonic Healthcare Ltd (ASX: SHL) and Cedar Woods Properties Ltd (ASX: CWP), that lead their respective sectors and could strengthen your income strategy.

Sonic Healthcare

This isn't the flashy ASX growth darling grabbing headlines. Sonic Healthcare is the steady compounder. The ASX dividend share that just keeps turning the crank.

It's defensive by design. Recession or boom, patients still need blood tests, biopsies, and scans. Diagnostic demand is essential, recurring, and far less exposed to consumer sentiment than most industries.

Sonic's pathology and imaging network spans Australia, Europe, the US, and the UK. That global footprint gives it multiple earnings engines and built-in diversification if one region slows. Few ASX healthcare names match that spread.

The structural tailwinds are clear. Ageing populations and the shift toward preventative medicine mean more testing over time, not less. Rising volumes drive reliable cash flow, while disciplined bolt-on acquisitions have expanded scale without wrecking margins.

And then there's the income stream.

With a market cap around $10 billion, Sonic pays dividends twice a year and has built a long track record of maintaining – and gradually growing – payouts.

Bell Potter forecasts partially franked dividends of 109 cents per share in FY26 and 111 cents in FY27. At a recent share price of $23.14, that equates to yields of roughly 4.7% and 4.8%.

Brokers see upside, too. The consensus 12-month price target sits near $25.59, implying 10.6% potential gains. Bell Potter is more bullish, with a buy rating and a $28.50 target — suggesting upside closer to 23%.

Cedar Woods Properties

Cedar Woods is a focused residential developer with one big advantage: control. The ASX dividend share owns a sizeable land bank across key growth corridors, giving it the flexibility to release stock when market conditions suit.

That discipline has helped it generate steady cash flow, fund dividends, and avoid the excessive leverage that trips up many property peers.

The strength here is simplicity. The ASX real estate stock sticks to what it knows: master-planned communities and well-located residential projects. And it executes with a conservative balance sheet. In a housing market undersupplied for years, that's a powerful position.

But let's be clear: this is still a cyclical business. Earnings can be lumpy, settlements can shift between periods, and higher interest rates or softer buyer sentiment can quickly slow sales. Construction costs also remain a risk if margins tighten.

The outlook? Australia's housing shortage hasn't disappeared. Population growth and limited supply should support medium-term demand.

Cedar Woods is well placed to convert its pipeline into rising earnings and dividends. The ASX dividend share just declared a fully-franked interim dividend of 14 cents per share, up 40% on last year's interim dividend of 10 cents per share.

Bell Potter believes the ASX dividend share is well-positioned to benefit from Australia's chronic housing shortage.

The broker expects this to support dividends per share of 35 cents in FY 2026 and then 39 cents in FY 2027. Based on its current share price of $8.60, this equates to 4.1% and 4.5% dividend yields.

The post Chasing income? These top ASX dividend shares could deliver appeared first on The Motley Fool Australia.

Two that have fared well and been given buy ratings following their results releases are named below. Here's why Morgans remains bullish on these stocks:

IPH Ltd (ASX: IPH)

Morgans continues to recommend this intellectual property services company to clients.

In response to its half-year results, the broker has put a buy rating and $5.39 price target on the ASX dividend stock. It said:

IPH's 1H26 result was broadly in line with consensus, reporting like-for-like (LFL) revenue and EBITDA growth at the group level. Whilst Canada and Asia showed growth, ANZ remains impacted by lower US PCT filings. IPH's valuation is undemanding (<8x FY27F PE), however we note investor patience is required given the delivery of organic growth (and return of key US PCT's) looks to be the catalyst for a sustained re-rating. Maintain Buy recommendation.

As for income, Morgans is forecasting fully franked dividends of 38 cents per share in FY 2026 and then 39 cents per share in FY 2027. Based on its current share price of $3.67, this equates to very generous dividend yields of 10.3% and 10.6%, respectively.

Sonic Healthcare Ltd (ASX: SHL)

Another ASX dividend stock that is rated highly by the team at Morgans is Sonic Healthcare.

It responded to its better than expected half-year results by retaining its buy rating with a trimmed price target of $28.64. It said:

1HFY26 result was better than expected, with underlying NPAT c4% ahead and organic revenue growth of 5%, demonstrating resilience across most regions. Underlying EBITDA was broadly in line, margins expanded and cost discipline remained evident. Importantly, FY26 guidance was maintained, an operational review of the US business is underway, and sale-and-leaseback activity introduces capital management optionality.

While structural growth remains moderate, we view the result as evidence that the market's "broken core" narrative has been overstated. Execution now becomes the key driver, but at subdued trading levels, the risk/reward skews favourably. We adjust FY26-28 estimates (mainly FX related), with our target price decreasing to A$28.64. BUY.

With respect to income, the team at Morgans is expecting Sonic Healthcare to reward shareholders with dividends per share of $1.08 in FY 2026 and then $1.11 in FY 2027. Based on its current share price of $23.02, this would mean dividend yields of 4.7% and 4.8%, respectively.

The post Morgans says these buy-rated ASX dividend stocks offer yields up to 10% appeared first on The Motley Fool Australia.

It's worth asking whether the business is a good buy at this valuation, given it rose around 10% on the day of the report.

Let's first remind ourselves what the business reported by looking at the numbers that were revealed.

HY26 earnings recap

The pathology business reported that revenue grew 17% to $5.4 billion in the first half of FY26. Within this growth, there was an organic growth of 5%.

Earnings grew at a good pace, though not as fast as the revenue growth. Operating profit (EBITDA) climbed by 10% to $907 million, net profit increased 11% to $262 million, earnings per share (EPS) grew 8% to 53.1 cents, and operating cash flow rose 10% to $682 million. These numbers allowed the business to increase its interim dividend by 2.3% to 45 cents per share.

It wasn't a surprise to see that its German revenue increased 52% to $1.36 billion, thanks to the LADR acquisition, which settled on 1 July 2026. Organic revenue grew by 5%, and, combined with synergies and cost control, this led to a higher profit margin. Germany made around a quarter of the ASX 200 healthcare share's total revenue.

Australian pathology delivered organic revenue growth of 5% (and total revenue of $1.08 billion) while the USA saw total revenue growth of 3% to $1.05 billion (and no organic growth)

Impressively, the UK segment delivered 24% organic growth and 30% total growth to $489 million. The ASX 200 healthcare share benefited from a number of new contracts.

Is the Sonic Healthcare share price a buy?

After reviewing the result, broker UBS noted that management is prioritising EPS and return on invested capital (ROIC), with a review and restructuring in the US, as well as plans to sell and lease back properties in Australia, which could support a share buyback.

UBS noted that Sonic (and its peers) are lobbying for more government funding to cover the increased wages mandated by the Fair Work Commission ruling, to ensure the same quality of service. The broker is sceptical that the government will increase funding amid broader budgetary pressures, so margin headwinds seem "unavoidable".

The broker highlighted that Sonic is delivering weaker organic growth than peers in the US, including the loss of an Alabama contract. Meanwhile, the new NHS contract was an impact on markets, but supports full-year revenue growth.

UBS also thinks the US restructuring is "sensible but does not address the core issue: declining market share as larger peers consolidate via hospital deals". Sonic "has not participated in this trend and risks being left behind."

The broker has a neutral rating on the ASX 200 healthcare share, with a price target of $21.80, suggesting a decline over the year ahead. UBS forecasts the business can grow net profit to $597 million in FY26 and $646 million in FY27.

The post Is this ASX 200 healthcare share a great buy after reporting? appeared first on The Motley Fool Australia.

If you are, then it could be worth checking out the three ASX 200 shares in this article.

That's because they have been tipped to rise between 20% and 40% by analysts at Bell Potter. Here's what they are recommending:

Aristocrat Leisure Ltd (ASX: ALL)

Bell Potter thinks that this gaming technology company's shares could have major upside potential.

This morning, the broker has retained its buy rating on the ASX 200 share with a $70.00 price target (from $80.00). Based on its current share price of $50.33, this implies potential upside of approximately 40% for investors over the next 12 months. It said:

We retain our Buy recommendation. We continue to expect ALL's leading R&D investment will drive market share gains. Top 2 game performance observed in both the core sales and premium gaming ops markets leaves us confident that ALL can grow the install base >4.0k per year and grow global shipments. Further, with leverage standing at 0.2x, ALL has substantial M&A firepower to boost growth inorganically.

Bega Cheese Ltd (ASX: BGA)

Another ASX 200 share that Bell Potter expects to rise strongly is diversified food company Bega Cheese. This morning, in response to its half-year results, the broker has retained its buy rating with an improved price target of $7.75 (from $7.00). Based on its current share price of $6.21, this suggests that upside of 25% is possible for investors.

Bell Potter believes the Vegemite owner can achieve its $250 million EBITDA target in 2027. It said:

Our Buy rating is unchanged. BGA's >$250m EBITDA target is in reach and achieved by executing on capital investment and site consolidation initiatives already underway. Trading on a FY26e PE of 26.9x for three-year compound EPS growth of 24% p.a. BGA is a compelling GARP play and one of the few exposures on the ASX leveraged to the growing consumer preference for higher protein formats, through both its branded portfolio and specialised ingredient platform.

Sonic Healthcare Ltd (ASX: SHL)

Finally, this healthcare company's shares could be undervalued according to Bell Potter. It has retained its buy rating on the ASX 200 share with a slightly improved price target of $28.75 (from $28.50). Based on its current share price of $23.34, this implies potential upside of 23%.

Bell Potter was relatively pleased with Sonic Healthcare's half-year results and has lifted its earnings estimates. It said:

We have made modest changes to our earnings estimates across FY26e-FY28e with increases to EPS of 1.7%/1.4%/1.3%. The result is a c.1% upgrade in our TP to $28.75/sh, which represents c.23% upside to the current share price. We expect this result to support investor sentiment, which has struggled in recent times, with the prospect of trading multiples reverting toward long-term averages.

The post These ASX 200 shares could rise 20% to 40% appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

Today's intraday peak beat the last record set on 21 October last year.

The new high follows robust results from some of Australia's largest companies, as earnings season continues today.

Strongly rising oil prices overnight have also lifted the ASX 200 today on concerns that US military action in Iran may be imminent.

At the time of writing, the ASX 200 is 9,102.5 points, up 1.06%.

Let's review some of today's strongest results.

Shares driving the ASX 200 higher today

ASX 200 communications is the top-performing market sector after Telstra Group Ltd (ASX: TLS) shares hit a 9-year high.

Telstra shares rose 5.6% to $5.24 after the telco reported a 10% lift in its underlying net profit after tax (NPAT) to $1.2 billion for 1H FY26.

ASX 200 industrial sector heavyweight Brambles Ltd (ASX: BXB) saw its shares lift 6.4% to an intraday high of $25 per share.

Brambles reported a 7% increase in its underlying and operating profit (constant currency) to US$792 million for 1H FY26.

ASX 200 healthcare large-cap Sonic Healthcare Ltd (ASX: SHL) ripped 14% to an intraday peak of $24.14 per share. 

The pathology and radiology services provider reported an 11% increase in NPAT to $262 million for 1H FY26.

ASX 200 financial sector mid-cap Hub24 Ltd (ASX: HUB) skyrocketed 21% to an intraday high of $104.21 per share.

The wealth management platform provider revealed an 80% lift in statutory NPAT and increased its interim dividend by 50%.

Hub24 shares are the fastest risers on the ASX 200 today.

Energy is the second strongest sector on Thursday, primarily due to higher oil prices.

Analysts at Trading Economics said:

Reports indicated that any US military action would likely unfold as a weeks-long campaign, with Israel's government advocating an outcome aimed at regime change in the Islamic Republic. 

Unemployment remains at 4.1%

The ASX 200 hit a new record despite stronger-than-expected jobs data released today.

This morning, the Australian Bureau of Statistics revealed that unemployment stayed steady in January at 4.1%.

The ABS said the number of workers rose by 18,000. This was comprised of 50,000 new full-time jobs and 33,000 fewer part-time jobs.

According to reporting in the Australian Financial Review (AFR), the consensus market expectation was 4.2% and 20,000 new jobs.

Generally speaking, strong jobs data adds to the case for further interest rate hikes to combat resurgent inflation.

The Reserve Bank of Australia lifted the cash rate for the first time in more than two years this month.

The post ASX 200 lifts to record high amid strong earnings and new jobs data appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are racing higher:

Hub24 Ltd (ASX: HUB)

The Hub24 share price is up 13% to $97.73. This follows the release of the investment platform provider's half-year results. Hub24 reported a 26% increase in revenue to $245.9 million and a 60% jump in underlying net profit after tax to $68.3 million. The company's managing director and CEO, Andrew Alcock, commented: "These results demonstrate our continued momentum, with record net inflows and strong progress in delivering our strategy to create value for customers and shareholders. Our recognition again as Australia's best platform reflects our commitment to delivering innovative solutions that enable advisers to support the needs of their clients throughout their life stages and empower better financial futures for more Australians, which is now more important than ever."

Sonic Healthcare Ltd (ASX: SHL)

The Sonic Healthcare share price is up 13% to $24.03. Investors have been buying the healthcare company's shares following the release of its half-year results. Sonic posted a 17% increase in revenue to $5.45 billion and an 11% lift in net profit to $262 million. This allowed the company's board to declare an interim dividend of 45 cents per share, which was up 2.3% on last year. Sonic Healthcare's CEO, Dr Jim Newcombe, said: "Sonic Healthcare's first half result demonstrated the strength and global diversity of the group's operations. We consistently deliver high-value medicine to our global communities and are a trusted partner for doctors, patients and healthcare systems."

Telstra Group Ltd (ASX: TLS)

The Telstra share price is up 5% to $5.21. This has been driven by the release of a solid half-year result from the telco giant this morning. For the six months ended 31 December, Telstra reported a 14% increase in cash EBIT. This underpinned an increase in its interim dividend to 10.5 cents per share (from 9.5 cents per share). Telstra's CEO, Vicki Brady, said: "We delivered ongoing growth in earnings, reflecting momentum across our business, strong cost control and disciplined capital management."

Universal Store Holdings Ltd (ASX: UNI)

The Universal Store share price is up 6.5% to $8.95. Investors have been buying the youth fashion retailer's shares after it impressed with its half-year results. Universal Store posted a 14.2% increase in sales over the prior corresponding period to $209.6 million. Growing even stronger was the company's underlying net profit, which was up 22% to $28.3 million.

The post Why Hub24, Sonic, Telstra, and Universal Store shares are racing higher today appeared first on The Motley Fool Australia.

At the time of writing, the Sonic Healthcare share price is up 12.29% to $23.84.

Here's what the company reported.

Double-digit revenue and earnings growth

For the six months ended 31 December 2025, Sonic Healthcare delivered a solid performance across its global operations.

Key highlights included:

• Revenue up 17% to $5.45 billion

• EBITDA up 10% to $907 million

• Net profit up 11% to $262 million

• Cash generated from operations up 10% to $682 million

• Earnings per share (EPS) up 8% to 53.1 cents

Management said the result was underpinned by strong organic growth, disciplined cost control, and improving operational performance across most regions.

Sonic confirmed it remains on track to achieve its previously issued full-year EBITDA guidance of $1.87 billion to $1.95 billion on a constant currency basis.

By sticking with its earnings outlook, the company signalled that trading conditions remain supportive. It also indicates margin discipline is holding, even as parts of the healthcare sector face ongoing cost pressures.

Dividend lifted again

Sonic declared an interim dividend of 45 cents per share, up 2.3% on last year. The dividend will be 60% franked.

Key dates to note are:

• Ex-dividend date: 4 March 2026

• Record date: 5 March 2026

• Payment date: 19 March 2026

The company said its progressive dividend policy remains intact, targeting a payout ratio of 70% to 80% of net profit.

Performance across key regions

Several of Sonic's key markets posted solid growth.

Germany delivered strong statutory revenue growth of 52%, boosted by acquisitions and solid organic momentum. The UK reported revenue growth of 30%, driven by new NHS contracts and private-sector wins.

In Australia, pathology revenue grew 5% organically, supported by Medicare indexation and strength in the specialist and hospital segments. Radiology also saw organic revenue growth of 7%, aided by higher value modalities such as MRI and PET.

The United States posted more modest growth, with revenue up 3% on a statutory basis. Management acknowledged margin pressure in parts of the US business but said multiple improvement initiatives are underway.

Capital management initiatives

Sonic also outlined capital management priorities, including maintaining its balance sheet and selectively pursuing acquisitions.

The company is progressing a sale and leaseback of its Brisbane hub laboratory, with estimated proceeds of $450 million to $500 million, targeting completion in June 2026.

There is also potential for share buybacks using surplus capital from property transactions.

Foolish Takeaway

Sonic Healthcare's half-year result delivered a solid mix of earnings growth, steady margins, a higher dividend, and reaffirmed full-year guidance.

After a challenging period for global healthcare stocks, today's 12% surge points to renewed confidence in Sonic's outlook.

With diversified global operations, tight cost control, and reaffirmed guidance, Sonic looks well placed for FY26.

The post Why Sonic Healthcare shares are rocketing 12% on blockbuster half-year results appeared first on The Motley Fool Australia.

Will the market be able to build on this on Wednesday? Here are five things to watch:

ASX 200 to rise again

The Australian share market looks set to rise on Wednesday after a decent night on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 54 points or 0.6% higher this morning. In late trade in the United States, the Dow Jones is up 0.25%, the S&P 500 is up 0.4% and the Nasdaq is 0.5% higher.

Oil prices fall

ASX 200 energy shares Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a poor session on Wednesday after oil prices tumbled into the red overnight. According to Bloomberg, the WTI crude oil price is down 0.9% to US$62.33 a barrel and the Brent crude oil price is down 1.8% to US$67.42 a barrel. Traders were selling oil down after Iran made progress with its nuclear talks with the United States.

NAB shares on watch

National Australia Bank Ltd (ASX: NAB) shares will be on watch on Wednesday when it becomes the last of the big four to release an update this month. The rest of the major banks delivered solid updates, so expectations are high for this one. Also scheduled to release results today are Sonic Healthcare Ltd (ASX: SHL), Lottery Corporation Ltd (ASX: TLC), and Suncorp Group Ltd (ASX: SUN).

Gold price sinks

ASX 200 gold shares such as Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) could have a difficult session on Wednesday after the gold price sank overnight. According to CNBC, the gold futures price is down 2.9% to US$4,899.3 an ounce. Traders were selling gold (and silver) as they awaited delayed economic data and responded to easing US-Iranian tensions.

CBA shares go ex-dividend

Commonwealth Bank of Australia (ASX: CBA) shares are going ex-dividend this morning and could trade lower. Last week, Australia's largest bank released its half-year results and reported a cash net profit of $5.45 billion. This was an increase of 6% on the prior corresponding period and allowed the CBA board to declare a fully franked interim dividend of $2.35 per share. Eligible CBA shareholders can look forward to receiving this payout next month on 30 March.

The post 5 things to watch on the ASX 200 on Wednesday appeared first on The Motley Fool Australia.

But both Santos Ltd (ASX: STO) and Sonic Healthcare Ltd (ASX: SHL) are quality companies and now sit at more compelling prices.

For investors chasing a mix of income and potential upside, the 2 ASX dividend shares could be worth a closer look.

Santos

The first ASX dividend share has found fresh momentum, climbing about 8% this year to $6.70 as oil prices rebound and investors rotate back into energy.

The story is shifting. Santos is emerging from a heavy spending phase just as major projects near completion. That timing matters.

At its core, the ASX dividend share owns long-life oil and LNG assets across Australia, Papua New Guinea, Timor-Leste, and the US. LNG under long-term contracts helps steady cash flow when spot prices swing.

Now the growth projects loom large. Barossa LNG and Alaska's Pikka oil development are edging toward first production. If delivered on time and on budget, they should lift output, free cash flow, and earnings power. In a few years, Santos could look leaner, higher-margin, and more cash-generative.

Income adds to the appeal. The stock currently offers a dividend yield of around 5.4%, well above the broader market. Management has tightened its capital return framework, linking dividends directly to free cash flow rather than stretching the balance sheet. That's more disciplined — but not immune to commodity cycles.

Still, if prices hold and projects deliver, Santos offers income plus upside. Consensus broker targets sit around $7.22, an 8% capital upside from here, before dividends. The team at Macquarie has an outperform rating and a 12-month price target of $7.77, which would be a 16% return from the current share price.

Sonic Healthcare

This ASX dividend stock isn't the flashy growth name stealing headlines. Sonic Healthcare is the steady compounder. The ASX dividend share that keeps delivering.

This is a defensive business by design. When the economy slows, people still need blood tests, biopsies, and scans. Diagnostic demand is essential, recurring, and far less sensitive to consumer confidence than most sectors.

The ASX dividend share's pathology and imaging network stretches across Australia, Europe, the US, and the UK. That global footprint gives it multiple earnings engines and a natural hedge if one region softens. Few ASX healthcare shares can match that diversification.

The structural tailwinds are hard to ignore. Ageing populations and the shift toward preventative healthcare mean more testing, not less. Higher volumes support steady cash flow, while management's disciplined acquisition strategy has added scale without blowing out margins.

Then there's the dividend.

The $10 billion ASX dividend share pays shareholders twice a year and has a long history of maintaining — and gradually increasing — payouts. Bell Potter expects partially franked dividends of 109 cents per share in FY26 and 111 cents in FY27.

At a recent share price of $21.20, that implies yields of roughly 5.1% and 5.2%. Brokers are cautiously optimistic, with an average 12-month price target of $25.65, suggesting a potential upside of 21%.

Analysts at Bell Potter have a buy rating and a $28.50 price target on its shares. This suggests a 34% upside.

The post 2 quality ASX dividend shares trading at a discount appeared first on The Motley Fool Australia.